These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15919698)

  • 21. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
    Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
    Al-Akash SI; Al Makadma AS; Al Omari MG
    Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ups and downs of sirolimus in kidney transplantation, and the importance of reporting negative findings.
    van Gelder T
    Neth J Med; 2007 Jan; 65(1):3-4. PubMed ID: 17293633
    [No Abstract]   [Full Text] [Related]  

  • 25. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.
    Campistol JM; Cockwell P; Diekmann F; Donati D; Guirado L; Herlenius G; Mousa D; Pratschke J; San Millán JC
    Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
    J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sirolimus offers advantages for kidney transplant patients].
    Med Klin (Munich); 2003 Feb; 98(2):VII. PubMed ID: 12638547
    [No Abstract]   [Full Text] [Related]  

  • 29. Costimulation blockade with belatacept in renal transplantation.
    Dharnidharka VR
    N Engl J Med; 2005 Nov; 353(19):2085-6; author reply 2085-6. PubMed ID: 16282187
    [No Abstract]   [Full Text] [Related]  

  • 30. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
    Ponticelli C
    Transplant Proc; 2001; 33(1-2):1031-2. PubMed ID: 11267177
    [No Abstract]   [Full Text] [Related]  

  • 33. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
    Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
    Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection.
    Mathew TH; Van Buren C; Kahan BD; Butt K; Hariharan S; Zimmerman JJ
    J Clin Pharmacol; 2006 Jan; 46(1):76-87. PubMed ID: 16397287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive strategies to improve outcomes of kidney transplantation.
    Tang IY; Meier-Kriesche HU; Kaplan B
    Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
    Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.